Siemens Healthineers plans to supply medical devices to IISc-associated hospitals: Staudinger

Germany’s Siemens Healthineers has tied up with the Indian Institute of Science in Bengaluru on clinical research projects and plans to supply medical devices to the upcoming hospitals and medical schools associated with the institute. The two parties signed a related memorandum of understanding on Tuesday, according to Elisabeth Staudinger, a managing board member at the German firm. In a conversation with DH’s Dhanya Skariachan and two other reporters, she shed light on the German medical device maker’s plans for India. Edited excerpts.

How important is India in your larger scheme of things?

India is a very important location as well as market. In terms of location, it – especially Bengaluru – is the hub where we have (an) almost 3500-people strong software development team, where we also over the years have started building a manufacturing base. And we are now in this transition of further elevating the role of the team here in Bengaluru to become one of the key nodes in our global innovation network. So we are really moving to making Bengaluru one of the key places where we also innovate and work on the future for Siemens Healthineers, both in India as well as globally.

Also Read: Protecting families from ruinous healthcare costs

Does India have the potential to become a manufacturing hub for medical devices?

Already today, we have a first product which was entirely designed, developed, engineered and … built in India. We originally created this product to address the specific needs of the market in India. But in the meantime, we have started exporting that product. To me, this is a real success story and a good example of how by starting from kind of a focus on the specific needs of the market here in India, we can create global success stories.

Has India become a meaningful manufacturing hub for you already?

For India to be a meaningful manufacturing base, it’s extremely important to have a strong supplier ecosystem around you. If you ship all the parts here and assemble them here, it’s not really meaningful. It doesn’t bring a lot of cost savings. On the contrary, it may even increase cost and it also doesn’t create jobs for people in India. So it’s not a win-win type of setup and you can really create a win-win type of setup if, in addition to locating your own production manufacturing here in India, you also make sure you have as many parts that you need from your local supply base. And this is something which takes some time. This doesn’t happen overnight. But, step by step, we are building that ecosystem around us, which will allow us over time to further expand.

What fuels your optimism tied to the Indian market?

If you look at the metro areas in India, you have very good hospitals. Very, I mean, maybe sometimes difficult to afford for some patients, but the quality of care is excellent. If you go to more rural areas, yeah, even basic things sometimes are not there. And this is why we believe there is still a significant need to provide better access to care to people in India. And this also makes us very optimistic about the future market development here in the country.

Also Read: Gender inequalities, inequities in healthcare, clinical research are alive!

How will you make healthcare services more accessible and affordable in India?

I’m actually quite confident here that we have very meaningful value products available, which can make a difference in these places. However, spending the money on putting a piece of equipment somewhere…is not really enough to be able to offer services to patients which make a difference. In order to do this, you need qualified staff, you need physicians, you need nurses, you need people who know how to diagnose a disease and to recommend them and follow up on a treatment. And this is where digitalisation really can make a difference. You can leverage digitalisation in many different ways. It starts from training people. It can be about providing the scanning service from a metro location (such) that you don’t need the specialised personnel on the ground here, which sometimes may be very difficult. So you can do things remotely. If you look at diagnostic information, be it lab results or imaging tests, the doctor who looks at the images can sit anywhere, right? If you use digital tools, you can send this information to wherever the expert is and send the diagnosis back. So digitalisation is a key enabler when it comes to providing better access to care.

Could you shed some light on your collaboration with IISc? 

This morning, we had a meeting with the Indian Institute of Science, where we are also entering into closer collaborations to really capture this idea of creating an innovation hub here in Bengaluru. And in that context, there are also certain discussions around corporate social responsibility in the collaboration with IISc here in Karnataka, so it’s a bit of a different angle. But it’s also a way where we bring our expertise together with people here in the ecosystem who then multiply the impact together with us.
(IISc’s upcoming hospital on campus) will focus on not only training doctors, but it will also focus on this aspect of bringing science into medicine. So they want to develop programs where you have training as a medical doctor together with a PhD. And this is something which fits very well with who we are and how we work. So because we are the partners, to a certain extent, on the technological side. (We are) helping them with, kind of, building a strong research base, to go a bit beyond just providing medical services, but really look for pioneering healthcare.

How does India compare with China w.r.t. its position on the global healthcare map?

China may be a bit further down the road when it comes to really providing good access to healthcare to their populations. We are very optimistic about India. We do believe that the dynamics here in India, both in the economy, but also when it comes to providing better health care services will be positive over the next years to come. And this is also why we are now focusing here in India, investing here in India, building a manufacturing base, moving up the food chain, also in the software development work to becoming an innovation hub, because we believe that India, I mean, already today, it’s not small, but it will become an even more important element in our global network going forward.

What are the cutting-edge technologies you are heavily invested in right now? 

There’s three pillars which make us unique. The first is what we call patient twinning. So this is our ability based on imaging, based on the blood testing, to enable a very early, very precise diagnosis, which then helps guide treatment. And this is extremely important. For the treatment to be effective, the better the diagnosis, the earlier the diagnosis, the cheaper it is to be treated, and the more effective the treatment will be. Then we have strengths when it comes to precision therapy. And this revolves around leveraging robotics, to guide therapy and make therapy ultra precise, which again, has significant benefits for patients. One really good example is in cancer therapy, where we provide the equipment that destroys tumours in the body. You use a very high energy radiation to do this. And this is harmful. You want to make sure that you only and very precisely only expose this part of the body which you want to treat, and that you spare everything else. So this is one area where we have absolute strengths and where we keep innovating because there is still a lot which can be improved. And these two pillars are all founded in our ability to work with digitalisation data, and artificial intelligence. And especially that pillar is enabled here by the work we do here in Bengaluru.

In 2020, you unveiled plans to invest ₹1,300 crore in an innovation hub in Bengaluru. Could you give us an update on where things stand now?

Tomorrow’s the groundbreaking ceremony for the investment we’re making here. The state-of-the-art facility, which is something we are really excited about, will bring together all the different disciplines we have in the company. We have our strong software development team, the innovation centre, the manufacturing footprint as well as our headquarters for India. So the people who work with customers here in India, who service our installed base in the country, everybody will be co located here in Bengaluru. And we believe that this will be a very interesting space, which can also drive innovation.

Are you planning to hire more people in India?

We have about 7000 employees in India, about half of those are based out of Bengaluru. We expect that we will add another 1800 people in the years to come. The building will be ready by 2025. Then, we will have the facilities to then, over time, add this additional headcount.

WARP Partners with Supply Chain Fitness to Give Drivers a Fresh Start in 2023

Los Angeles – WARP, a tech-driven network of cross-docks and carriers specializing in middle-mile remedies, now introduced a new partnership with Supply Chain Health (SCF). SCF, led by bodily therapist Dr. Mark Manera, gives customized work out, nourishment, and accountability coaching for the whole offer chain community. WARP is offering a range of compensated memberships to the TruckFit program that will enable experienced motorists kickstart their health and fitness and training journey in 2023.

Dr. Mark Manera, SCF’s founder, observed firsthand what a lifetime of trucking can do to a person’s overall body, whilst rehabbing drivers in a bodily treatment clinic. Harmful drivers are not only a hazard to them selves, but the corporations that they function for. Wholesome and happier drivers direct to improved retention, reduced overall health premiums, greater employee satisfaction fees, lessened perform comp promises and in general greater enterprise society. SCF’s coaching personnel also features a registered dietitian, accredited own trainers, and wellness coaches.

“When WARP approached us about partnering to tackle the wellbeing worries that drivers encounter on a day to day basis, we knew that they ended up distinct from a typical brokerage,” stated Dr. Mark Manera, Founder of Source Chain Health and fitness. “It’s apparent that WARP not only cares deeply about their shippers, but also the drivers, fleets and people today that transfer freight 24/7/365.”

Lots of companies in the freight place have designed unbelievable adaptive technologies but it lacks connectivity to the person, the human driving the automobile. WARP pairs shippers with carriers dependent on the masses that fits into their potential and equipment kind (sprinter vans, box trucks, and 53 footers) in each market to make guaranteed they can employ their several hours of functions and crank out far more revenue from their fleets.

“Making healthy alternatives when you’re on the street all the time can be definitely hard if you don’t have the appropriate steering and sources,” Blake Borek, extended haul driver. “I’d listened to about Supply Chain Conditioning earlier, but didn’t know precisely what they ended up all about so when I saw that WARP was delivering a totally free membership I jumped at the option to master much more. I just cannot say adequate good things about how they’ve created my lifetime easier. This software understands the rough life-style of trucking and has tons of unique training and nutrition options to enable accommodate my everyday living on the street!”

The TruckFit program is wholly personalised to meet just about every driver in which they are at, with a application customized to in good shape their way of life like workouts motorists can do in their truck, routine based habits adjust program, and common balanced life style tips. They also have 24/7 entry to information a mentor with any inquiries and will get a weekly test-in text to keep them accountable to their plans.

“69{bf0515afdcaddba073662ceb89fbb62b6b1bf123143c0e06b788e1946e8c353f} of very long-haul drivers are obese and have a lifetime expectancy 16 decades fewer than the normal individual,” explained Daniel Sokolovsky, WARP CEO and Co-Founder. “As a sufferer of Kind 1 Diabetes, I’ve normally struggled with building healthier options while on the road. Many really don’t know that my initial small business was meals delivery, and I spent a lot of time in the vehicle and it can be amazingly hard to make time for health or select wholesome alternatives. This is our way to pay back it forward to all the motorists out there performing the do the job, day in and out. At WARP, we want to be part of the alternative, not the difficulty.”

ABOUT WARP

WARP is a modern freight community bringing peace of brain to shippers. With its heterogeneous fleet of 53-footers, box trucks, and cargo vans, WARP offers clients the proper auto for each load primarily based on their speed, price, and service choices. By pairing proprietary tech with a wide community of carriers and cross-docks, WARP automatically optimizes middle-mile routes via a one built-in platform, supplying shippers unparalleled visibility of their hundreds. Whether or not it can be a immediate retailer shipping, warehouse-to-warehouse transfers, or linehaul injection into previous mile carriers, WARP shoppers acquire authentic-time tracking and status updates alongside with devoted support every phase of the way.

ABOUT Provide CHAIN Health and fitness

Source Chain Physical fitness delivers trucking and logistics corporations a aggressive advantage in retention and threat mitigation by marketplace-foremost workout, nutrition, and accountability coaching.

https://wearewarp.com

Exclusive: EU to propose delay to medical device law amid supply worries

LONDON, Dec 8 (Reuters) – The EU Well being Commissioner will on Friday suggest extending the deadline for organizations to comply with a new legislation regulating healthcare gadgets, she instructed Reuters on Thursday as medical professionals alert the laws is creating shortages of lifesaving products.

Stella Kyriakides informed Reuters that worries in employing the regulation had been threatening provides of vital gadgets, this kind of as catheters applied for surgeries on newborns with coronary heart conditions.

“Our individuals hope that medical gadgets are harmless and of maximum quality. We have created important progress to set in area new needs for individual security, but troubles however stay,” mentioned Kyriakides in published emailed comments to Reuters.

“This is why, to mitigate any brief-term pitfalls, we will tomorrow announce an extension of the changeover time period to mitigate any danger of shortages.”

Kyriakides will make the proposal at a meeting of EU health and fitness ministers on Friday. She reported in parliament previous month she was contemplating amendments.

A Commission supply said the extension will need an modification to the legislation. Any authorized adjustments would need to have to be authorised by the Council and Parliament.

Kyriakides did not comment on how extensive the extension would be for.

The Healthcare Products Regulation (MDR) came into effect final 12 months and was launched immediately after the 2010 scandal of exploding breast implants created by a French organization that exploited loopholes to provide defective products at profit.

It has extra stringent needs and greater safety benchmarks than the directive it replaced.

Below the new law, all health-related devices, from implants and prosthetics to blood glucose meters and pacemakers sold in the EU need to be re-licensed by May possibly 2024.

A dozen health professionals and producers interviewed by Reuters say supplies of some merchandise are running lower even just before the 2024 deadline.

That is simply because certificates which very last for 5 many years beneath the aged program are expiring and companies are having difficulties to get new types beneath the new legislation. They say the new certification system is sluggish, cumbersome and expensive.

“From the standpoint of medical practitioners, the circumstance is starting to be extra and much more stressing. We are by now observing shortages of some vital healthcare devices, and in a lot of circumstances option products are lacking,” Christiaan Keijzer, president of the Standing Committee of European Doctors (CPME), told Reuters.

He reported that healthcare associations throughout Europe have noted complications with the provide of surgical instruments, in particular in paediatrics, orthopaedics and cardiology, as very well as other gadgets these kinds of as binocular endoscopes, silicone adhesives and blood assortment items.

Facts unveiled by the Fee in a assertion this 7 days ahead of Friday’s conference highlights the issue.

Makers have submitted apps for around 8,000 devices, but a lot less than 2,000 have been permitted.

At that speed, only 7,000 certificates less than the new program will be issued by the May well 2024 deadline, the Commission explained.

The Fee reported there are about 23,000 certificates less than the outdated system which will expire by Could 2024 without having an extension. About 4,300 of those will expire subsequent yr, it explained.

Certificates address a number of units, generating it challenging to estimate the full number of merchandise potentially affected.

Reporting by Maggie Fick editing by Josephine Mason and Elaine Hardcastle

Our Criteria: The Thomson Reuters Trust Ideas.

Royal Emerald Pharmaceuticals Partners with BioHarvest Sciences to Supply Disruptive Cannabis Solutions to Companies Conducting FDA-Approved Medical Research

This collaboration ensures first-of-their-kind consistent cannabinoid compositions for 575 DEA-licensed cannabis medical research institutions developing cures for PTSD, pain management, anxiety conditions and more

Vancouver, British Columbia and Rehovot, Israel–(Newsfile Corp. – November 16, 2022) –  BioHarvest Sciences (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV), a leading biotech company focused on plant bio-cells growth for the nutraceutical and the medicinal cannabis markets, today announced the signing of a binding Letter of Intent (LOI) with Royal Emerald Pharmaceuticals (REP), one of only seven Drug Enforcement Administration (DEA) bulk manufacturing registration holders permitted to grow marijuana in the United States for drug related studies approved by the US Food and Drug Administration. This follows BioHarvest’s October 25th announcement that it could produce unique compositions based on a CBD hemp plant that dramatically increase cannabinoid concentrations (by weight) versus the original plant.

The 3-year initial term (with extension provisions) exclusive arrangement allows the supply of BioHarvest cannabis products for research purposes to pharmaceutical companies, research institutions and other DEA registered entities in the United States federally, and opens the door to advance cannabis research initiatives for drug development through cannabinoid compositions not found in nature. Under the multi-year deal, BioHarvest will be REP’s exclusive provider of cannabis that is produced from non-traditional cultivation methods for scientific, medical and research purposes across the DEA-regulated U.S. market. As part of the LOI, REP has participated with $1 million in BioHarvest’s convertible loan investment instrument that closed its second tranche on November 15th.

Cannabis-based medicines could be a boon to pharmaceutical companies that are threatened today by the legalization of cannabis. A number of studies have demonstrated a reduction in prescription drug use in Medicaid and Medicare populations directly resulting from the legalization of cannabis. Together, REP and BHSC can offer pharmaceutical companies consistent medical-grade cannabis at highly attractive manufacturing costs with signature patentable compositions tailored for addressing specific medical indications.

“I have unprecedented confidence in BioHarvest’s platform technology and their unique cannabis compositions especially after visiting their R&D and manufacturing facilities in Israel,” said Douglas Rosenberg, Chief Executive Officer of Royal Emerald Pharmaceuticals. “Cannabis-derived drugs are at the precipice of a tremendous opportunity right now as traditional pharmaceutical markets transition in search of innovation and technological advancements that are utilizing cannabis to deliver better solutions. Together we are well-positioned for the expected significant increase in U.S. demand for medical-grade cannabis for therapeutic research. I look forward to a productive and mutually prosperous partnership.”

“We’re extremely proud to partner with Royal Emerald to pair our breakthrough technology with their mission to revolutionize the cannabis medical research ecosystem by introducing unique and patentable cannabis compositions that are non-addictive and effectively treat a myriad of issues currently ailing our global communities,” said BioHarvest CEO Ilan Sobel. ” BioHarvest and REP are committed to developing life-changing solutions for major medical conditions which today are not being adequately treated by existing, chemically synthesized drugs. Imagine what can be accomplished if researchers and the medical community at large are assured of batch-to-batch consistency and the ability to fine-tune the Cannabis based therapy to specific medical indications. That is truly revolutionary.”

Using a patented technology in which vital plant cells are grown in bioreactors, BioHarvest has the unique ability to produce medicinal grade cannabis with consistent compositions by increasing, controlling, and fine-tuning the concentrations of different major and minor cannabinoids. This could help researchers to potentially develop previously unattainable cures for major health challenges such as ADHD, pain management, sleep disorders, and anxiety.

Dr. Christopher D’Adamo, Director of the University of Maryland School of Medicine’s Center for Integrated Medicine, described BioHarvest’s technology as a major advancement.

“Today marks a historical milestone in the pioneering and development of future full-spectrum cannabis drugs which the medical establishment has been eyeing its potential to address many chronic health indications in need of better treatment options,” D’Adamo said. “In addition, BioHarvest’s ability to provide signature cannabis compositions with a breadth of cannabinoids, and with batch consistency and patentability, will no doubt be a major incentive for companies to actively engage and invest in Cannabis based drugs”.

REP is one of only seven companies in the U.S. that hold DEA bulk-manufacturing licenses for scientific medical research. It is permitted to provide cannabis to at least 575 institutions that have DEA research licenses for cannabis research. They range from pharmaceutical companies to academic and medical institutions to government agencies such as the Department for Veterans Affairs and the National Institute on Drug Abuse. REP also has a General Services Administration license which enables the company together with BioHarvest to apply for major government grants from government agencies for cannabis research.

Under the LOI, and subject to the obtainment of the Israeli health authorities manufacturing license, the cannabis products supplied by BioHarvest will be produced in the facility in Israel. The future establishment of a manufacturing facility at REP’s premises in California is contemplated under certain conditions. The LOI also includes provisions with respect to future potential development of medical drugs by BioHarvest, REP and jointly.

Investor Webinar – Wednesday November 16, 2pm EST | 11am PST

Given the magnitude of this announcement, and what it means for the pioneering of cannabis drug development to focus on major indications that today are not being adequately addressed by pharmaceutical drug companies, the Company will host a special investor event today at 11am PST | 2pm EST, where BioHarvest Sciences CEO Ilan Sobel will be joined by the CEO of Royal Emerald Pharmaceuticals, Douglas Rosenberg. All interested media and investors are invited to preregister via this link: https://us02web.zoom.us/webinar/register/WN_y44ONRvVQ9Ou5bhWtHrvAA

About BioHarvest Sciences Inc.

BioHarvest Sciences Inc. (CSE: BHSC) is a fast-growing biotech firm that has developed a patented bio-cell growth platform technology capable of growing the active and beneficial ingredients in fruit and plants, at an industrial scale, without the need to grow the plant itself. This technology is economical, ensures consistency, and avoids the negative environmental impacts associated with traditional agriculture. BioHarvest is currently focused on nutraceuticals and the medicinal cannabis markets. Visit: www.bioharvest.com.

About Royal Emerald Pharmaceuticals

Royal Emerald Pharmaceuticals is a California-based United States DEA and FDA-registered manufacturer and supplier of non-addictive cannabis products being developed for medical, scientific and research purposes. The company was founded on a shared mission to help veterans, first responders and others service personnel on the front lines that sacrifice for the greater good and as a result suffer from trauma-related issues such as PTSD and other health consequences. Royal Emerald is dedicated to serving our heroes by developing best-in-class cannabis derived pharmaceuticals to address their specific health and medical needs. Visit: https://www.royalemeraldrx.com/.

Contact:

BioHarvest Sciences Inc.
Ilan Sobel, Chief Executive Officer

For further information, please contact:
Dave Ryan, VP Investor Relations & Director Phone: 1 (604) 622-1186
Email: info@bioharvest.com

Royal Emerald Pharmaceuticals
Douglas Rosenberg, Chief Executive Officer

For further information, please contact:
Jackie Devereaux, Director of Communications & Media Relations
Phone 1 (760) 671-6944
Email: jdevereaux@royalemeraldrx.com

Forward Looking Statements

Information set forth in this news release includes forward-looking statements that are based on management’s current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Projected sales of Cannabis products will require the Company to obtain production and/or export licensing which cannot be assured. There is no assurance that the Company’s products will help researchers working on medications for heath challenges such as ADHD, sleep disorders. pain management and anxiety. Marketing products with such claims would require FDA approval in the US and similar approvals in other jurisdictions which would require a lengthy and expensive approval process including clinical trials the outcome of which would be uncertain and cannot be assured. Although the Company believes that the consistency and customizability of its products will make them more suitable for medical and scientific research there is no assurance that the customers of Royal Emerald or other medical/scientific users of cannabis products will choose the Company’s products over traditionally grown Cannabis Products. Adoption of new and disruptive products can be subject to structural obstacles and the uncertainty of market acceptance which may delay or even prevent adoption. There is no assurance that the Company and /or Royal Emerald will develop medical drugs which normally involves lengthy and expensive research and approval processes which may be beyond the ability of these parties and significant uncertainty of success.

All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.

Royal Emerald Pharmaceuticals Partners with BioHarvest Sciences to Supply Disruptive Cannabis Solutions to Companies Conducting FDA-Approved Medical Research

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/144473